These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 9827814

  • 1. Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report.
    Linker CA, Ries CA, Damon LE, Rugo HS, Wolf JL.
    Bone Marrow Transplant; 1998 Nov; 22(9):865-72. PubMed ID: 9827814
    [Abstract] [Full Text] [Related]

  • 2. Busulfan plus etoposide as a preparative regimen for autologous bone marrow transplantation for acute myelogenous leukemia: an update.
    Linker CA, Damon LE, Ries CA, Rugo HS, Wolf JL.
    Semin Oncol; 1993 Aug; 20(4 Suppl 4):40-8; quiz 49. PubMed ID: 8342075
    [Abstract] [Full Text] [Related]

  • 3. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up.
    Ball ED, Wilson J, Phelps V, Neudorf S.
    Bone Marrow Transplant; 2000 Apr; 25(8):823-9. PubMed ID: 10808202
    [Abstract] [Full Text] [Related]

  • 4. High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Zander AR, Berger C, Kröger N, Stockshläder M, Krüger W, Horstmann M, Grimm J, Zeller W, Kabisch H, Erttmann R, Schönrock P, Kuse R, Braumann D, Illiger HJ, Fiedler W, de Witt M, Hossfeld KD, Weh HJ.
    Clin Cancer Res; 1997 Dec; 3(12 Pt 2):2671-5. PubMed ID: 10068272
    [Abstract] [Full Text] [Related]

  • 5. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
    Kröger N, Zabelina T, Sonnenberg S, Krüger W, Renges H, Stute N, Finkenstein F, Mayer U, Holstein K, Fiedler W, Colberg H, Sonnen R, Kuse R, Braumann D, Metzner B, del Valle F, Erttmann R, Kabisch H, Zander AR.
    Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
    [Abstract] [Full Text] [Related]

  • 6. 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemia.
    Rizzieri DA, Talbot JT, Long GD, Vredenburgh JJ, Gasparetto C, Smith CS, Colvin MO, Adams D, Morris A, Dodge R, Loftis J, Waters-Pick B, Reese M, Carawan H, Koh LP, Chao NJ.
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):183-8. PubMed ID: 12652469
    [Abstract] [Full Text] [Related]

  • 7. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [Abstract] [Full Text] [Related]

  • 8. Autologous bone marrow transplantation for patients with acute myeloblastic leukemia in relapse after autologous blood stem cell transplantation.
    de la Rubia J, Sanz GF, Martín G, Sempere A, Picón I, Carral A, Larrea L, Martínez J, Soler MA, Bonanad S, López F, Jarque I, Sanz MA.
    Bone Marrow Transplant; 1996 Dec; 18(6):1167-73. PubMed ID: 8971390
    [Abstract] [Full Text] [Related]

  • 9. Autologous bone marrow transplantation for acute myelogenous leukemia using 4-hydroperoxycyclophosphamide and VP-16 purged bone marrow.
    Gulati S, Acaba L, Yahalom J, Reich L, Motzer R, Crown J, Doherty M, Clarkson B, Berman E, Atzpodien J.
    Bone Marrow Transplant; 1992 Aug; 10(2):129-34. PubMed ID: 1525601
    [Abstract] [Full Text] [Related]

  • 10. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission.
    Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E, Willman C, Hurd DD, Bennett JM, Blume KG, Head DR, Wiernik PH.
    N Engl J Med; 1998 Dec 03; 339(23):1649-56. PubMed ID: 9834301
    [Abstract] [Full Text] [Related]

  • 11. Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purged marrows for children with acute non-lymphoblastic leukemia in second remission.
    Lenarsky C, Weinberg K, Petersen J, Nolta J, Brooks J, Annett G, Kohn D, Parkman R.
    Bone Marrow Transplant; 1990 Dec 03; 6(6):425-9. PubMed ID: 2097012
    [Abstract] [Full Text] [Related]

  • 12. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
    Visani G, Lemoli R, Tosi P, Martinelli G, Testoni N, Ricci P, Motta M, Gherlinzoni F, Leopardi G, Pastano R, Rizzi S, Piccaluga P, Isidori A, Tura S.
    Bone Marrow Transplant; 1999 Sep 03; 24(5):467-72. PubMed ID: 10482929
    [Abstract] [Full Text] [Related]

  • 13. Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
    Jerjis S, Roovers E, Muus P, Schaap N, de Witte T.
    Bone Marrow Transplant; 1998 Jul 03; 22(1):13-9. PubMed ID: 9678790
    [Abstract] [Full Text] [Related]

  • 14. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
    Tomás JF, Gómez-García de Soria V, Pinilla I, Lamana M, Figuera A, Arranz R, Cámara R, Fernández-Villalta MJ, Alegre A, Fernández-Rañada JM.
    Med Clin (Barc); 1997 Feb 15; 108(6):201-6. PubMed ID: 9102484
    [Abstract] [Full Text] [Related]

  • 15. Delayed engraftment of 4-hydroperoxycyclophosphamide-purged autologous bone marrow after induction treatment containing mitoxantrone for acute myelogenous leukemia.
    Damon LE, Rugo HS, Ries CA, Linker CA.
    Bone Marrow Transplant; 1996 Jan 15; 17(1):93-9. PubMed ID: 8673063
    [Abstract] [Full Text] [Related]

  • 16. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation.
    Wadehra N, Farag S, Bolwell B, Elder P, Penza S, Kalaycio M, Avalos B, Pohlman B, Marcucci G, Sobecks R, Lin T, Andrèsen S, Copelan E.
    Biol Blood Marrow Transplant; 2006 Dec 15; 12(12):1343-9. PubMed ID: 17162217
    [Abstract] [Full Text] [Related]

  • 17. Comparison of preparative transplantation regimens using carmustine/etoposide/cisplatin or busulfan/etoposide/cyclophosphamide in lymphoid malignancies.
    Crilley P, Lazarus H, Topolsky D, Ciobanu N, Creger RJ, Fox RM, Bulova SI, Shina DC, Gucalp R, Cooper BW.
    Semin Oncol; 1993 Aug 15; 20(4 Suppl 4):50-4; quiz 55. PubMed ID: 8342076
    [Abstract] [Full Text] [Related]

  • 18. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
    Ortega JJ, Díaz de Heredia C, Olivé T, Bastida P, Llort A, Armadans L, Torrabadella M, Massuet L.
    Haematologica; 2003 Mar 15; 88(3):290-9. PubMed ID: 12651268
    [Abstract] [Full Text] [Related]

  • 19. Single-institution results of autologous bone marrow transplantation in acute myeloid leukemia.
    Lambertenghi Deliliers G, Annaloro C, Della Volpe A, Oriani A, Mozzana R, Pozzoli E, Tagliaferri E, Soligo D.
    Haematologica; 1995 Mar 15; 80(2):136-41. PubMed ID: 7628752
    [Abstract] [Full Text] [Related]

  • 20. Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia.
    Miggiano MC, Gherlinzoni F, Rosti G, Bandini G, Visani G, Fiacchini M, Ricci P, Testoni N, Motta MR, Geromin A, Rizzi S, Belardinelli A, Mangianti S, Manfroi S, Tura S.
    Leukemia; 1996 Mar 15; 10(3):402-9. PubMed ID: 8642854
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.